RORobert A. Overman

Robert A. Overman

*This is an algorithmically generated author record based on publicly available information.

Robert A. Overman has a total of 125 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Critical density triplets for the arrestment of a sphere falling in a sharply stratified fluid

    by Roberto Camassa, Lingyun Ding, Richard M. McLaughlin, Robert Overman, Richard Parker, Ashwin Vaidya

    We study the motion of a rigid sphere falling in a two-layer stratified fluid under the action of gravity in the potential flow regime. Experiments at a moderate Reynolds number of approximately 20 to 450 indicate that a sphere with the precise critical density, higher than the bottom layer density, can display behaviors such as bounce or arrestment after crossing the interface. We experimentally demonstrate that such a critical sphere density increases linearly as the bottom fluid density increases with a fixed top fluid density. Additionally, the critical density approaches the bottom layer fluid density as the thickness of density transition layer increases. We propose an estimation of the critical density based on the potential energy. With assuming the zero layer thickness, the estimation constitutes an upper bound of the critical density with less than 0.043 relative difference within the experimental density regime 0.997 $g/cm^{3}$ $\sim $ 1.11 $g/cm^{3}$ under the zero layer thickness assumption. By matching the experimental layer thickness, we obtain a critical density estimation with less than 0.01 relative difference within the same parameter regime.

  • Open Access

    Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation

    by Jennifer A. Rymer, Katherine E. Mues, Keri L. Monda, Emily W. Bratton, Heidi S. Wirtz, Ted Okerson, Robert A. Overman, M. Alan Brookhart, Paul Muntner, Tracy Y. Wang

    Background: Proprotein convertase subtilisin/kexin type 9 inhibitors ( PCSK 9i) are used to reduce low‐density lipoprotein ( LDL ) cholesterol. PCSK 9i use after initiation, as well as persistence with or alterations to other LDL ‐lowering therapy after PCSK 9i initiation, is not well understood. Methods and Results: We conducted a retrospective study of alirocumab or evolocumab ( PCSK 9i) new users from July 2015 to December 2017 in the MarketScan Early View database of US commercial insurance beneficiaries. We determined the prevalence of PCSK 9i interruption (≥30‐day gap in supply) and LDL ‐lowering therapy use in the year after PCSK 9i initiation. The average age of 6151 patients initiating PCSK 9i therapy was 63 years, 44.4% were women, and 76.8% had atherosclerotic cardiovascular disease. Overall, 52.2% (95% CI , 50.8%–53.7%) of patients had an interruption in PCSK 9i therapy in the first year after treatment initiation and 62.5% remained on PCSK 9i therapy at 1‐year postinitiation. Also, 27.7% of patients were taking a statin at the time of PCSK 9i initiation, with only 22.4% on statin therapy at 1 year after PCSK 9i initiation. Ezetimibe use decreased from 20.9% at the time of PCSK 9i initiation to 12.0% a year later. By 1 year after PCSK 9i initiation, 44.0% of patients had experienced an interruption in all LDL ‐lowering therapies, and 26.6% were no longer on any LDL ‐lowering therapies. Conclusions: After PCSK 9i initiation, statins were often discontinued, whereas more than half of patients experienced an interruption in PCSK 9i therapy. These results suggest that many new PCSK 9i users may remain at high risk for cardiovascular events because of interruptions in LDL ‐lowering therapy.


  • Open Access

    Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States

    by Leah J McGrath, Karynsa Kilpatrick, Robert A Overman, Diane Reams, Anjali Sharma, Ivy Altomare, Jeffrey Wasser, M Alan Brookhart

    Purpose: Patients with immune thrombocytopenia (ITP) have low platelet counts and an increased risk of bleeding. We described treatment patterns and clinical outcomes in routine practice in the United States (US). Patients and Methods: Using electronic health record data from hematology/oncology clinics linked to administrative claims in the US, we studied 447 adults newly diagnosed with primary ITP from 2011 to 2016. Patients with a secondary cause of thrombocytopenia were excluded. The incidence of ITP treatment initiation, bleeding events, and rescue therapy use were estimated using competing risk models. Results: At 1-year post-ITP diagnosis, 50% of patients were prescribed an oral corticosteroid, with the majority being prescribed immediately following diagnosis. Of the more common second-line options, rituximab use was the most frequent (1-year cumulative incidence: 16% [95% confidence interval: 12, 19]), followed by romiplostim (9% [7, 12] and eltrombopag (5% [3, 8]). Use of these drugs was similar at 2 years post-diagnosis. At 6 months post-ITP treatment initiation, the cumulative incidence of bleeding was similar among eltrombopag and romiplostim initiators (17% [6, 33] and 19% [9, 31], respectively) and was slightly lower in rituximab users (12% [6, 20]). However, during this same timeframe, rituximab users had a higher incidence of rescue therapy use (48% [36, 58] versus 29% [14, 46] in eltrombopag and 26% [14, 39] in romiplostim users). Although splenectomy was rare, at 6 months post-surgery nearly 20% had experienced a bleed and nearly 20% had required rescue. Conclusion: This study describes the health trajectory of adults with ITP who are managed in hematology clinics in the US and could inform the design of non-interventional studies of comparative effectiveness among treatments.


  • Open Access

    Trends in Chronic Opioid Use Around Inpatient Surgery Within the Veterans Health Administration

    by Karthik Raghunathan, Neil Ray, William Bryan, Marc Pepin, Robert Overman, Atilio Barbeito, Vijay Krishnamoorthy

    In a large national sample within a managed care organization, incident long-term opioid therapy (LTOT) after surgery occurred in approximately 6% of preoperatively opioid-naive patients between 2013 and 2014.1 Because veterans have more chronic pain than the general population,2 incident LTOT may be more common within the Veterans Health Administration (VHA). We sought to examine incident postoperative LTOT and incident postoperative cessation of opioid use between 2000 and 2016 within the VHA, a time frame spanning the prescription opioid epidemic.3


  • Impact of an Opioid Safety Initiative on Patients Undergoing Total Knee Arthroplasty

    by Qi Chen, Hung-Lun Hsia, Robert Overman, William Bryan, Marc Pepin, Edward R. Mariano, Seshadri C. Mudumbai, Thomas Buchheit, Vijay Krishnamoorthy, Chester B. Good, et al.

    Editor’s Perspective: What We Already Know about This Topic: What This Article Tells Us That Is New: Background: The Opioid Safety Initiative decreased high-dose prescriptions across the Veterans Health Administration. This study sought to examine the impact of this intervention (i.e., the Opioid Safety Initiative) on pain scores and opioid prescriptions in patients undergoing total knee arthroplasty. Methods: This was an ecological study of group-level data among 700 to 850 patients per month over 72 consecutive months (January 2010 to December 2015). The authors examined characteristics of cohorts treated before versus after rollout of the Opioid Safety Initiative (October 2013). Each month, the authors aggregated at the group-level the differences between mean postoperative and preoperative pain scores for each patient (averaged over 6-month periods), and measured proportions of patients (per 1,000) with opioid (and nonopioid) prescriptions for more than 3 months in 6-month periods, preoperatively and postoperatively. The authors compared postintervention trends versus trends forecasted based on preintervention measures. Results: After the Opioid Safety Initiative, patients were slightly older and sicker, but had lower mortality rates (postintervention n = 28,509 vs. preintervention n = 31,547). Postoperative pain scores were slightly higher and the decrease in opioid use was statistically significant, i.e., 871 (95% CI, 474 to 1,268) fewer patients with chronic postoperative prescriptions. In time series analyses, mean postoperative minus preoperative pain scores had increased from 0.65 to 0.81, by 0.16 points (95% CI, 0.05 to 0.27). Proportions of patients with chronic postoperative and chronic preoperative opioid prescriptions had declined by 20% (n = 3,355 vs. expected n = 4,226) and by 13% (n = 5,861 vs. expected n = 6,724), respectively. Nonopioid analgesia had increased. Sensitivity analyses confirmed all findings. Conclusions: A system-wide initiative combining guideline dissemination with audit and feedback was effective in significantly decreasing opioid prescriptions in populations undergoing total knee arthroplasty, while minimally impacting pain scores.


  • Open Access

    Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States

    by Leah J. McGrath, Rohini K. Hernandez, Robert Overman, Diane Reams, Alexander Liede, M. Alan Brookhart, Elizabeth O’dOnnell

    Background: Prior to 2018, intravenous bisphosphonates (IV BPs) were the only therapies recommended to prevent skeletal‐related events for patients diagnosed with multiple myeloma (MM). We examined patterns of IV BP initiation and interruption among patients with newly diagnosed MM (NDMM) in the United States.Methods: Electronic health records linked to administrative health insurance claims were used to identify adults with NDMM between 1 January 2011 and 30 April 2016. Patients were excluded for recent IV BP use or concurrent cancer. The incidences of IV BP initiation and interruption were estimated using competing risk regression. A generalized linear model was used to estimate risk factors for treatment initiation and interruption.Results: Among the 547 patients with NDMM, 64% initiated MM therapy within 30 days of diagnosis. By one year, 65% (95% CI: 59, 70) of patients with appropriately timed anti‐MM therapy had initiated an IV BP. Zoledronic acid was the most commonly initiated IV BP. Patients with Stage III MM were more likely to initiate an IV BP (adjusted risk difference (RD): 6.3; 95% CI: 2.7, 10.1), while those with eGFR <30 mL/min were less likely to initiate (RD: −9.7; 95% CI: −13.8, −5.8). Of the 264 patients who initiated an IV BP, 77% (95% CI: 71, 82) experienced an interruption within one year. Patients on concurrent anti‐MM therapy were less likely to experience an interruption in IV BP therapy.Conclusions: Many patients with NDMM do not initiate IV BPs, particularly those with renal complications. Interruptions of IV BPs were common.


  • Open Access

    Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US

    by Leah J McGrath, Robert A Overman, Diane Reams, Karynsa Cetin, Alexander Liede, Steven A Narod, M Alan Brookhart, Rohini K Hernandez

    Purpose: Bone-modifying agents (BMAs) are recommended for women with bone metastasis from breast cancer to prevent skeletal-related events. We examined the usage patterns and identified the factors associated with the use of BMAs (denosumab and intravenous bisphosphonates) among women in the US. Patients and methods: Electronic health records from oncology clinics were used to identify women diagnosed with bone metastasis from breast cancer between 2013 and 2014. Patients were excluded if they had recently used a BMA or had concurrent cancer at an additional primary site. The incidence of BMA initiation, interruption, and reinitiation were estimated using competing risk regression models. A generalized linear model was used to estimate risk factors for treatment initiation and interruption. Results: There were 589 women diagnosed with bone metastasis from breast cancer. By 1 year, 68% of these patients (95% CI: 64%, 71%) had initiated treatment with a BMA. Denosumab and zoledronic acid were the most commonly used agents, whereas pamidronate was used infrequently. Young women were more likely to initiate a BMA than older women (adjusted risk difference: 6.4 [95% CI: 1.5, 10.9]). Of the 412 patients who initiated a BMA, 46% (95% CI: 41%, 51%) experienced an interruption within 1 year. Seventy-four percent (95% CI: 68%, 79%) of patients who interrupted their treatment had reinitiated therapy within 1 year of interruption. Conclusion: The majority of women diagnosed with bone metastasis from breast cancer initiate a BMA within 1 year of diagnosis, but a large proportion, particularly among the elderly, do not use these therapies.


  • Treatment dynamics of bone‐targeting agents among men with bone metastases from prostate cancer in the United States

    by Anne M. Butler, Karynsa Cetin, Rohini K. Hernandez, B. Diane Reams, Robert A. Overman, Jung I. Kim, Bradford R. Hirsch, Amy P. Abernethy, Alexander Liede, M. Alan Brookhart

    Purpose: To examine the dynamics of treatment with 2 bone‐targeting agents (BTAs)—denosumab and zoledronic acid—among men with bone metastases from prostate cancer.Methods: Using electronic health record data from oncology practices across the US, we identified prostate cancer patients diagnosed with bone metastasis in 2012/2013 without evidence of BTA use within 6 months prior to diagnosis. We examined the risk and predictors of BTA initiation, interruption, and re‐initiation.Results: Among 897 men diagnosed with prostate cancer, the cumulative incidence of BTA initiation after bone metastasis diagnosis was 34% (95% confidence interval [CI], 31–37%) at 30 days, 64% (95% CI, 61–68%) at 180 days, and 88% (95% CI, 85–91%) at 2 years. Denosumab was initiated more frequently than zoledronic acid. Men with diabetes, more bone lesions, history of androgen deprivation therapy, or no hospice enrollment were more likely to initiate treatment. Following initiation, the cumulative incidence of treatment interruption was 17% (95% CI, 14–19%) at 60 days and 70% (95% CI, 66–74%) at 2 years, with interruption more likely among patients receiving emerging therapies for prostate cancer or enrolling in hospice. The cumulative incidence of re‐initiation following interruption was 36.3% (95% CI, 32.7–40.2%) at 15 days, 49.8% (95% CI, 45.9–54.1%) at 30 days, and 81.0% (95% CI, 77.5–84.7%) at 1 year.Conclusions: Bone‐targeting agent therapy is initiated by the majority of men living with bone metastases following a prostate cancer diagnosis; however, the timing of initiation is highly variable. Once on treatment, gaps or interruptions in therapy are common.


  • Open Access

    Correction to: Comparison of fracture risk assessment tools in older men without prior hip or spine fracture: the MrOS study

    by for the Osteoporotic Fractures in Men (MrOS) Study Group, Margaret L. Gourlay, Victor S. Ritter, Jason P. Fine, Robert A. Overman, John T. Schousboe, Peggy M. Cawthon, Eric S. Orwoll, Tuan V. Nguyen, Nancy E. Lane, et al.

    Owing to an oversight by the authors, the acknowledgments were incomplete.


  • Comparison of fracture risk assessment tools in older men without prior hip or spine fracture: the MrOS study

    by Margaret L. Gourlay, Victor S. Ritter, Jason P. Fine, Robert A. Overman, John T. Schousboe, Peggy M. Cawthon, Eric S. Orwoll, Tuan V. Nguyen, Nancy E. Lane, Steven R. Cummings, et al.

    Summary Femoral neck bone mineral density (BMD), age plus femoral neck BMD T score, and three externally generated fracture risk tools had similar accuracy to identify older men who developed osteoporotic fractures. Risk tools with femoral neck BMD performed better than those without BMD. The externally developed risk tools were poorly calibrated. Introduction We compared the performance of fracture risk assessment tools in older men, accounting for competing risks including mortality. Methods A comparative ROC curve analysis assessed the ability of the QFracture, FRAX® and Garvan fracture risk tools, and femoral neck bone mineral density (BMD) T score with or without age to identify incident fracture in community-dwelling men aged 65 years or older (N = 4994) without hip or clinical vertebral fracture or antifracture treatment at baseline. Results Among risk tools calculated with BMD, the discriminative ability to identify men with incident hip fracture was similar for FRAX (AUC 0.77, 95% CI 0.73, 0.81), the Garvan tool (AUC 0.78, 95% CI 0.74, 0.82), age plus femoral neck BMD T score (AUC 0.79, 95% CI 0.75, 0.83), and femoral neck BMD T score alone (AUC 0.76, 95% CI 0.72, 0.81). Among risk tools calculated without BMD, the discriminative ability to identify hip fracture was similar for QFracture (AUC 0.69, 95% CI 0.66, 0.73), FRAX (AUC 0.70, 95% CI 0.66, 0.73), and the Garvan tool (AUC 0.71, 95% CI 0.67, 0.74). Correlated ROC curve analyses revealed better diagnostic accuracy for risk scores calculated with BMD compared with QFracture (P < 0.0001). Calibration was good for the internally generated BMD T score predictor with or without age and poor for the externally developed risk tools. Conclusion In untreated older men without fragility fractures at baseline, an age plus femoral neck BMD T score classifier identified men with incident hip fracture as accurately as more complicated fracture risk scores.